GlassScriptPhysician profile
Anthony W Inmon
NPI 1972055606
$5,496.94
in general payments reported to CMS, 2019-2025
45 companies · $956 in 2025
The $956 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $479 · 2023: $1,837 · 2024: $2,225 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,006 · Education: $11.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,005.67 |
| Education | $11.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,096.12 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $427.81 | 2023-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $359.69 | 2022-2025 | Mavenclad |
| Ucb, INC. | $343.43 | 2022-2025 | Briviact, Rystiggo, Zilbrysq |
| Argenx US, INC. | $320.03 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $241.78 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $240.19 | 2023-2025 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $225.13 | 2022-2025 | |
| Pfizer INC. | $186.64 | 2024-2025 | |
| Axsome Therapeutics, INC. | $171.92 | 2023-2024 | Auvelity, Sunosi |
| Lilly USA, LLC | $138.58 | 2023-2025 | Emgality, Kisunla, Amyvid |
| Tanabe Pharma America, INC. | $138.35 | 2024 | |
| Biogen, INC. | $132.71 | 2023-2025 | Vumerity, Tysabri, Skyclarys |
| Lundbeck LLC | $122.53 | 2022-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $114.79 | 2022-2024 | Rytary, Crexont |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $111.77 | 2024 | Intellis Adaptivestim |
| Alexion Pharmaceuticals, INC. | $84.08 | 2023-2024 | Ultomiris |
| Acorda Therapeutics, INC | $83.03 | 2023 | Inbrija, Ampyra |
| Avion Pharmaceuticals | $74.34 | 2022-2023 | Dhivy |
| Abbott Laboratories | $73.56 | 2023-2025 | Infinity |
| Amylyx Pharmaceuticals, INC. | $69.37 | 2023 | Relyvrio |
| Livanova USA, INC. | $65.65 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Kyowa Kirin, INC. | $60.16 | 2022-2024 | Nourianz |
| Janssen Pharmaceuticals, INC | $59.97 | 2022-2023 | Ponvory |
| Genzyme Corporation | $57.51 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $54.85 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $43.76 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $41.79 | 2023 | Keveyis, Gvoke Hypopen |
| Averitas Pharma INC. | $39.48 | 2023-2024 | Qutenza |
| Eisai INC. | $31.73 | 2022-2024 | |
| Merz Pharmaceuticals, LLC | $27.01 | 2025 | Xeomin |
| Biohaven Pharmaceutical Holding Company LTD. | $25.35 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.08 | 2024 | Hyqvia |
| Horizon Therapeutics Plc | $24.26 | 2023 | Uplizna |
| Corium, LLC | $22.91 | 2023 | Adlarity, Adlarity |
| Tg Therapeutics, INC. | $21.44 | 2025 | |
| Genentech USA, INC. | $20.11 | 2022-2023 | Ocrevus |
| Banner Life Sciences, LLC | $17.95 | 2024 | |
| Mallinckrodt Hospital Products INC. | $15.95 | 2023 | Acthar |
| Chiesi USA, INC. | $15.48 | 2024 | Elfabrio |
| Mdd US Operations, LLC | $15.41 | 2023 | Apokyn |
| Sumitomo Pharma America, INC. | $14.61 | 2024 | Aptiom |
| Grifols USA, LLC | $14.21 | 2023 | Gamunex-C |
| Acadia Pharmaceuticals INC | $13.87 | 2023 | Nuplazid |
| Amicus Therapeutics, INC. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Inmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.